The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Innerscope Hearing Technologies 9-Day RSI Related Terms
INND vs NWCN, NCAP, MOBQ: 9-Day RSI Comparison
For the Medical Instruments & Supplies subindustry, Innerscope Hearing Technologies's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innerscope Hearing Technologies 9-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Innerscope Hearing Technologies's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Innerscope Hearing Technologies's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innerscope Hearing Technologies (INND) has a 9-Day RSI of 42.59 as of Jul. 12, 2026.
Is Innerscope Hearing Technologies' 9-Day RSI too high?
Innerscope Hearing Technologies' current 9-Day RSI is 42.59. The Medical Devices & Instruments industry median 9-Day RSI is 48.74. Innerscope Hearing Technologies' value of 42.59 is 12.6% below this industry median.
How does Innerscope Hearing Technologies' 9-Day RSI compare to NWCN and NCAP?
Innerscope Hearing Technologies' 9-Day RSI of 42.59 can be compared against companies in the Medical Devices & Instruments industry. The industry median 9-Day RSI is 48.74. Innerscope Hearing Technologies' value of 42.59 is 12.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Medical Devices & Instruments company?
The median 9-Day RSI among Medical Devices & Instruments companies is 48.74, based on 869 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innerscope Hearing Technologies's current 9-Day RSI of 42.59 is 12.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median 9-Day RSI is 48.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innerscope Hearing Technologies's current 9-Day RSI is 42.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innerscope Hearing Technologies stock overvalued right now?
Innerscope Hearing Technologies (INND) has a current 9-Day RSI of 42.59. The current 9-Day RSI is 42.59 and 12.6% below the Medical Devices & Instruments industry median of 48.74. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Innerscope Hearing Technologies (INND), the current 9-Day RSI is 42.59 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Innerscope Hearing Technologies Business Description
Innerscope Hearing Technologies Inc is a manufacturer and distributor of OTC Hearing Aids, Hearing Aid Accessories & Hearing Health-Related Products (Hearing Products) dedicated to addressing the demand for affordable hearing solutions. The company operates retail hearing device clinics in California. InnerScope is focused on leveraging these strategic assets to identify, incubate, and support health-technology ventures positioned for growth in public markets and long-term shareholder value creation.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INND has been successfully added to your